← All indications
Leiomyosarcoma
A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)
Drugs by status
Approved for this indication (1)
Phase 3 trials (15)
Phase 2 trials (56)
- fluorothymidine
- thalidomide
- saracatinib
- abemaciclib
- dexrazoxane
- rucaparib
- ridaforolimus
- avelumab
- urea
- sorafenib
- temsirolimus
- cixutumumab
- deoxycholic acid
- durvalumab
- eribulin
- fulvestrant
- vismodegib
- aldesleukin
- nivolumab
- ixabepilone
- pembrolizumab
- lenvatinib
- alisertib
- mocetinostat
- dinutuximab
- motexafin gadolinium
- niraparib
- olaratumab
- ipilimumab
- sunitinib
- +26 more
Phase 1 trials (15)
Organizations
Organization Involved with Phase 3 Indications (10)
Organization Involved with Phase 2 Indications (69)
- Bristol-Myers Squibb
- Clovis Oncology
- Imclone
- AstraZeneca
- Merck
- Merck Serono
- Genentech
- Merck KGaA
- Pfizer
- Novartis
- Ariad Pharmaceuticals
- ArQule
- Atara Biotherapeutics
- Bayer
- GlaxoSmithKline
- Oncolytics Biotech
- Sarcoma Oncology Research Center, LLC
- Chong Kun Dang Pharmaceutical
- National Institutes of Health (NIH)
- Javier Martín Broto, M.D.
- Medical University of Graz
- Centre Leon Berard
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- Temple University
- Gachon University
- University of Washington
- Grupo Espanol de Investigacion en Sarcomas
- Herbert Irving Comprehensive Cancer Center
- +39 more
Organization Involved with Phase 1 Indications (12)
Organization Involved with Other Experimental Indications (2)